Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NovaBay Pharmaceuticals Inc (NYSE MKT LLC:NBY)

3.40
Delayed Data
As of 3:59pm ET
 -0.11 / -3.13%
Today’s Change
1.63
Today|||52-Week Range
11.50
+68.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$39.5M

Company Description

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of compounds, Aganocides and NeutroPhase Skin and Wound Cleanser. The Company's four core business units, DermaBay, UroBay, EyeBay and MediBay, are developing treatments that tackle infections in the dermatology, urology, ophthalmology, and wound care areas. NovaBay Pharmaceuticals was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Contact Information

NovaBay Pharmaceuticals, Inc.
5980 Horton Street
Emeryville California 94608
P:(510) 899-8800
Investor Relations:
(510) 899-8809

Employees

Shareholders

Individual stakeholders53.83%
Other institutional0.47%
Mutual fund holders0.22%

Top Executives

Mark M. SieczkarekChairman, President & Chief Executive Officer
Tom PaulsonChief Financial Officer, Secretary & Treasurer
Justin M. HallSenior Vice President & General Counsel
Glenn MoroVice President-Sales & Marketing